How Private Equity Quietly Bought Your Doctor, Your Vet, and Your Dentist — And Why Everything Got Worse

UNITED STATES, May 22 — You sit down in the waiting room of a dental practice you have been visiting for years. The name on the door is the same. The receptionist might even be familiar. But somewhere in the past eighteen months, something changed. The appointment feels rushed. The dentist you trusted retired and was replaced by someone you have never met. And before you have even seen a clinician, a “patient education consultant,” not a doctor, is already discussing the cost of implants.

What changed, in all likelihood, is ownership. Private equity has been quietly acquiring medical practices, dental offices, veterinary clinics, and urgent care centers across the United States and beyond at a pace that most patients have never noticed and most politicians have been slow to address. In 2024 alone, private equity firms completed 1,136 unique healthcare deals in the United States, according to the Private Equity Stakeholder Project, including 148 buyouts, 728 add-on acquisitions, and 260 growth investments. The result is a fundamental transformation of who controls the places where people receive care, and the evidence on what that transformation means for patients is becoming increasingly difficult to ignore.

The Playbook: Buy, Roll Up, Extract

To understand what private equity does in healthcare, it helps to understand the basic financial model driving it.

A private equity firm raises a fund, typically with a five to seven-year investment horizon. It identifies a fragmented market, one where thousands of small, independent operators exist side by side without significant consolidation, and begins acquiring them. In healthcare, this means buying an independent dental practice, a veterinary clinic, or a physician group. That first acquisition becomes what is called a platform company. The firm then uses that platform to acquire dozens or hundreds of smaller practices in a process known as a roll-up, building scale, centralizing administration, and cutting costs wherever possible. The goal is to sell the consolidated entity at a significant profit before the fund’s investment horizon expires.

The model is not inherently malicious. In some industries, consolidation produces genuine efficiency gains that benefit consumers. But healthcare is not like most industries. It is a sector where the person receiving the service is often in pain, frequently frightened, almost always less informed than the person providing it, and sometimes in no position to shop around. The incentive structures that private equity introduces pressure to generate returns within a fixed window, pressure to increase revenue per patient, and pressure to reduce staffing costs interact with those vulnerabilities in ways that a growing body of research suggests are producing real harm.

What the Data Shows About Patient Outcomes

The evidence on private equity ownership and patient outcomes has accumulated rapidly over the past several years, and the findings are consistent enough to be alarming. A 2023 study published in the Journal of the American Medical Association examined 51 private equity-owned hospitals and found a 25% increase in hospital-acquired conditions for Medicare patients compared to control hospitals. That increase was driven by a 37.7% rise in bloodstream infections and a 27% rise in patient falls.

A separate study found that surgical site infections doubled at private equity-owned hospitals after acquisition, even as surgical volumes slightly decreased.

A 2025 study found that after acquisition, private equity-owned hospitals reduced salary and staffing in their emergency departments and intensive care units, alongside a 13.4% rise in deaths occurring in the emergency department. Patients transferred out of these facilities were, on average, sicker than those transferred from non-private equity hospitals, suggesting that the most complex and costly cases were being redirected rather than treated.

In dental care, the picture is equally troubling. Private equity affiliation with dental practices nearly doubled between 2015 and 2021, rising from 6.6% to 12.8%, with the fastest growth among specialists such as endodontists and oral surgeons. A 2024 exposé by KFF and CBS News documented a growing pattern at private equity-owned dental chains of dentists removing healthy teeth to profit from implant procedures that can cost tens of thousands of dollars, rather than recommending less expensive treatments like root canals. In at least one documented case, patients were meeting with sales representatives about implant costs before they had even been examined by a dentist.

A 2023 systematic review found that private equity ownership was consistently associated with cost increases for both patients and insurance payers. The full scope of these findings is documented through the Private Equity Stakeholder Project’s ongoing healthcare tracking , which represents one of the most comprehensive publicly available sources on private equity healthcare dealmaking.

Why Healthcare Is Such an Attractive Target

Private equity firms did not stumble into healthcare by accident. The sector has specific structural characteristics that make it highly attractive for the roll-up model.

Healthcare is extraordinarily fragmented. Hundreds of thousands of independent physician practices, dental offices, and veterinary clinics operate across the United States without the scale to negotiate effectively with insurers, invest in technology infrastructure, or withstand economic downturns. That fragmentation creates exactly the acquisition opportunity private equity looks for: a large number of small, relatively inexpensive targets that can be consolidated into a much more valuable platform.

Healthcare is also largely recession-proof. People need medical care regardless of economic conditions. Aging populations in developed countries mean increasing demand for a broad range of services. And reimbursement systems, whether private insurance or government programs like Medicare and Medicaid, provide a relatively predictable revenue stream that financial models can depend on.

Veterinary care has attracted particularly intense private equity interest for related reasons. Pet ownership surged during the pandemic, driving significant growth in veterinary spending. The veterinary sector was even more fragmented than human healthcare, dominated by small, independent clinics with limited bargaining power and largely unregulated compared to physician practices. By 2023, an estimated 25% of veterinary practices in the United States were owned by private equity-backed consolidators, a figure that continues to rise.

The combination of fragmentation, inelastic demand, and pricing power creates what private equity analysts describe as a compelling value proposition. What it creates for patients, human and animal alike, is something closer to a captive market.

One of the most consistent findings across research on private equity healthcare ownership is the relationship between acquisition and staffing reductions. The mechanism is straightforward. Labor is the highest cost in most healthcare practices. Reducing it through cutting positions, replacing experienced staff with less expensive alternatives, or simply running practices with fewer people than optimal produces the kind of margin improvement that makes financial models look better in the short term. The long-term consequences for quality of care are externalized onto patients and, in the case of serious adverse events, onto the broader healthcare system.

Physician burnout rates at private equity-owned practices are reported to be significantly higher than at independently owned counterparts. Doctors who sell their practices to private equity firms, often under financial pressure as healthcare costs rise and reimbursement rates stagnate, frequently describe a rapid loss of clinical autonomy after the transaction closes. Treatment decisions that were previously left to the clinician become subject to review by administrators focused on revenue optimization. Productivity targets replace professional judgment as the primary metric of performance. The Stanford Law Review’s 2024 analysis concluded plainly that private equity’s push for rapid revenue growth and quick exits means that private equity is not adding value to patient care. That assessment was based on a comprehensive review of available evidence at the time, and subsequent research has only reinforced it.

These dynamics connect to broader questions about how financial incentives are reshaping professional relationships in ways that affect far more than healthcare, a theme examined in how algorithmic systems are changing who wins and loses across complex industries .

The Bankruptcy Risk Nobody Warns Patients About

Beyond the quality-of-care concerns, private equity healthcare ownership carries a structural risk that patients rarely consider: the possibility that their provider will go bankrupt.

The private equity model frequently involves what is called a leveraged buyout, financing an acquisition largely with debt, which is loaded onto the acquired company rather than the acquiring firm. This means that the dental practice or hospital system that private equity just bought is carrying the debt used to purchase it, servicing that debt from its operating revenue while simultaneously trying to generate returns for investors. Steward Health Care, once the largest for-profit hospital chain in the United States after being acquired by Cerberus Capital Management in 2010, demonstrates how this ends. Steward sold nearly all its hospital properties to a real estate investment trust for $1.25 billion in 2016, using the cash to acquire more hospitals. The lease payments that resulted proved unsustainable. By early 2024, Steward filed for bankruptcy, forcing hospital closures and disrupting care for entire communities that had no warning their hospital was financially precarious until it was already too late.

Steward is the largest example, but not the only one. Private equity-backed healthcare bankruptcies have become common enough that researchers now track them as a distinct category of healthcare system failure. For patients, the consequences of closed facilities, disrupted relationships with providers, and loss of medical records can be severe.

Regulators and legislators have begun responding, though the pace has been slow relative to the scale of the problem. As of May 2025, at least 35 states require hospitals, health systems, physician groups, or private equity firms to notify state authorities of certain proposed healthcare transactions. Fifteen states have moved beyond notification to require formal review and approval. Massachusetts enacted legislation in January 2025 giving state regulators greater authority to review material change transactions, particularly those involving private equity.

At the federal level, proposed legislation has included measures that would require private equity owners to be personally liable for patient harm occurring at their healthcare facilities a significant departure from the standard limited liability structures that currently shield investors from the consequences of the decisions their ownership enables.

The full scope of state-level regulatory activity is documented through the National Academy for State Health Policy , which tracks model legislation across all 50 states.

Industry advocates argue that private equity investment has brought needed capital to underinvested healthcare markets, funded technology upgrades, and helped practices navigate the administrative complexity of modern healthcare reimbursement. These arguments are not entirely without merit; some acquisitions have genuinely improved operational efficiency without compromising care quality. But the weight of evidence suggests these cases are exceptions rather than the rule.

The tension between private capital’s role in healthcare and the public interest in accessible, safe, affordable care is not going away. It is, if anything, intensifying as private equity continues to expand into new healthcare subsectors, behavioral health, home care, and clinical trials, while the regulatory infrastructure struggles to keep pace.

This pattern of financial innovation outrunning oversight connects to broader dynamics explored in how private markets are opening up in ways that are reshaping who controls critical industries .

For most patients, the private equity ownership of their healthcare provider is invisible until something goes wrong. The name on the door does not change. The website looks the same. The insurance still accepts the practice.

There are practical steps worth taking. Before choosing a new provider, it is worth researching the ownership structure. Many private equity-backed healthcare platforms are large enough to have a public profile, and a brief search for the practice name alongside terms like “private equity” or the name of a dental services organization can reveal ownership. For existing providers, paying attention to changes in staffing turnover, appointment availability, and the presence of non-clinical staff in clinical conversations can be early indicators of ownership-driven pressure. For significant procedures, particularly expensive dental work, elective surgery, or any treatment recommended with unusual urgency, seeking a second opinion from an independent provider remains one of the most effective protections against over-treatment incentivized by profit targets rather than clinical need.

Full research on private equity’s impact on healthcare quality and patient outcomes is available through the American College of Health Information’s ongoing analysis , which represents one of the most accessible summaries of the peer-reviewed evidence for a general audience.

Private equity’s presence in healthcare is not a temporary phenomenon. Deal activity in 2025 reached record level